PTPA and neoplasm: Sorafenib (a new generation FLT3 mutant inhibitors) and vorinostat (a histone deacetylases inhibitor, HDAC) induce tumor-cell death through the induction of PP2A activity in C16 dihydroceramide-dependent manner (83).